Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry. [PDF]
BioDrugs, 2020 Objective The aim was to evaluate long-term drug retention, discontinuation, efficacy and safety of CT-P13 and reference infliximab in patients with rheumatoid arthritis (RA) enrolled in the Korean College of Rheumatology Biologics (KOBIO) registry ...
Kim HA +6 more
europepmc +6 more sources
Outcomes of an Intravenous to Subcutaneous Infliximab (CT‐P13) Strategy in Takayasu Arteritis: A Proof‐of‐Concept Prospective Study [PDF]
ACR Open RheumatologyObjectives To evaluate persistence, outcomes, safety, and remission maintenance after switching from intravenous infliximab (IV‐IFX) to subcutaneous infliximab (SC‐IFX, CT‐P13) in patients with Takayasu arteritis (TA). Methods We conducted a prospective,
Luca Iorio +6 more
doaj +2 more sources
Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice [PDF]
Intestinal Research, 2019 Background/Aims An interim analysis of post-marketing surveillance of CT-P13, an infliximab biosimilar, was performed to evaluate its safety and efficacy in Japanese patients with inflammatory bowel disease.
Tomoo Nakagawa +8 more
doaj +2 more sources
Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients [PDF]
Therapeutic Advances in Gastroenterology, 2016 Many reference biological therapies have now reached or are near to patent expiry, and therefore a number of biosimilars have been or will be developed.
Jørgen Jahnsen
doaj +3 more sources
Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score-Matched Analysis from the Korean College of Rheumatology Biologics Registry. [PDF]
BioDrugs, 2020 BACKGROUND: Long-term, real-world data are required to support the use of CT-P13 in chronic conditions such as ankylosing spondylitis. However, real-world evidence may be influenced by selection bias, which can confound outcomes.
Kim HA, Lee E, Lee SK, Park YB, Shin K.
europepmc +6 more sources
Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease [PDF]
Therapeutic Advances in Gastroenterology, 2018 Background: As the patents of originator biologics are expiring, biosimilar versions are becoming available for the treatment of inflammatory bowel disease (IBD).
Viktoria Bergqvist +11 more
doaj +2 more sources
Hemolytic anemia after switching from infliximab originator to biosimilar CT‐P13 in a patient with inflammatory bowel disease: A case report [PDF]
Clinical Case Reports, 2019 Available data on switching from originator infliximab to CT‐P13 in patients with inflammatory bowel disease are reassuring regarding safety and efficacy outcomes.
Anne S. Strik +2 more
doaj +2 more sources
Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases [PDF]
Therapeutic Advances in Gastroenterology, 2016 Infliximab was the first monoclonal antibody used in the treatment of inflammatory bowel disease (IBD). Over several years, this antitumour necrosis factor (TNF) treatment proved its efficacy in both induction and maintenance therapy.
Joanna Sieczkowska +4 more
doaj +3 more sources
Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial [PDF]
Rheumatology, 2021 Rene Westhovens +2 more
exaly +2 more sources
Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease. [PDF]
World J Clin Cases, 2021 In recent years, biological therapies have revolutionized the management of inflammatory bowel disease (IBD); however, they are expensive. The development of biosimilar products has allowed us to reduce healthcare costs and improve patients' access to these treatments.
Huguet JM +7 more
europepmc +6 more sources